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Abstract   
 
 
Background and aims:  
As part of a RCT in six European sites, the direct mental health care cost for 422 patients with 
schizophrenia was analysed according to how total, and medication costs differed across sites and 
which variables were likely to predict total or service-specific costs.  
 
Method: Service use was recorded continuously during a 12-month follow-up. Prescribed psycho-
tropic medication was recorded at baseline and 12 months later. Service use data were trans-
formed into EURO, log-transformed and analysed using linear regression models. 
 
Results:  
Although samples were homogeneous, large inter-site cost differences were found (annual means 
ranging from 2,958 € in Spain up to 36,978 € in Switzerland). Psychopharmacologic costs were 
much more constant across sites than costs for other services. Total costs were associated more 
with region or socio-demographic characteristics than with disorder related parameters. 
 
Conclusions:  
The findings confirm remarkable differences in direct costs of patients wit schizophrenia across 
Europe. However, the relative stability of medication costs suggests a need to analyse mecha-
nisms that influence service specific costs for schizophrenia. 
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1. Introduction 
 
Research on the costs of care for patients suffering from schizophrenia has increased 
during recent years. However, evidence is still scarce, as most studies target only se-
lected aspects of the wide range of treatments or services provided for patients with 
schizophrenia. A considerable proportion of research focuses on psychopharmacological 
treatment regimes and their economic consequences. This was stimulated by the need to 
evaluate whether or not the prescription of costly second-generation neuroleptic drugs, 
which were increasingly launched throughout the 1990s, is cost-effective in routine care. 
However, many of these cost-effectiveness studies preferred a decision model approach, 
feeding selected administrative, epidemiological, or clinical data into decision trees. The 
appropriateness of this approach is an issue of recent controversial debate (Hansen et al., 
2006; Beard et al., 2006; Barbui & Lintas; 2006). Follow-up studies assessing and analys-
ing psychopharmacologic drug consumption and the associated costs from a naturalistic 
perspective on a patient level are still scarce. Rarer still are cross-country comparisons 
that address total cost of care for patients suffering from schizophrenia with a particular 
focus on medication costs, as in this case, the diversity of international community mental 
health care models has to be controlled for. Such an approach multiplies the methodologi-
cal problems. Among the factors to be considered are varying price levels and funding 
mechanisms for mental health care, which are even more complex than the various com-
munity care concepts (Knapp et al., 2003; Windmeijer et al., 2006).  
 
Thus, very few macro-level comparisons of the cost of care for patients with schizophrenia 
across European countries are available to date, e.g., the EPSILON study (Knapp et al., 
2002), that compared service utilization and cost profiles of people with schizophrenia 
living in five European locations. The study found higher needs, greater symptom severity 
and longer psychiatric history being associated with higher costs. However, most of cost 
studies in this field often fail to link costs to outcomes of care, and they do not necessarily 
specify the cost of psychopharmacological drug use. In the face of recent doubts about 
the cost-effectiveness of second-generation antipsychotics informed by controversial find-
ings from various trials and meta-analyses (Rosenheck, 2006; Rosenheck et al., 2006; 
Jones et al. 2006; Davies et a.l. 2008; Zhu et al. 2008; Carpenter & Buchanan 2008), 
quantitative data in this field are fundamental to the ongoing transformation of community 
care systems. To bridge this gap, we analysed the total cost of care for patients with a 
diagnosis of schizophrenia in six countries as a part of a randomised controlled European 
trial, in which particular emphasis was put on the prospective recording of the cost of psy-
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chopharmacologic drug use on the patient level. The following research questions were 
addressed: 
• What are the overall costs and service-specific costs of care for patients with 
schizophrenia in the six sites and how do these differ across sites?  
• What variables predict total and service-specific costs of care across the sites?  
 
 
2. Material and Methods 
 
2.1 Study 
This randomised controlled trial was conducted in community psychiatric services in Gra-
nada (Spain), Groningen (the Netherlands) London (UK), Lund (Sweden), Mannheim 
(Germany) and Zurich (Switzerland), covering urban and mixed urban-rural areas.  
The original trial hypothesised that regular use of a novel computer-mediated procedure 
(called DIALOG) in routine meetings between clinicians and community patients with 
schizophrenia would be associated with a more favourable quality of life, fewer unmet 
needs for care, and higher treatment satisfaction after a one-year period as opposed to 
treatment as usual. By applying DIALOG, clinicians discussed regularly eleven life and 
treatment domains with the patients in the experimental group and asked them to rate 
their satisfaction with each domain. The rating was followed by a question as to whether 
the patients wanted any additional or different help in the given domain. The control group 
patients continued with standard treatment. The study design, study sample, settings, 
aims, and primary outcomes are described in detail elsewhere (Priebe et al., 2002; Priebe 
et al., 2007).  
 
In order to analyse the costs of mental health care for participating patients, the assess-
ments included a detailed prospective recording of mental health service use covering a 
12-month follow-up period. Additionally, for each patient the prescription of psychotropic 
medication (including type of drug, brand name, daily dosage and dosage form) was re-
corded at baseline and again 12 months later.  
The prime objective of the cost analyses (based on the service use and medication data) 
was to determine and analyse the total mental health care costs and service-specific 
costs, including psychopharmacologic drug cost for patients across all sites. In a second 
step, predictors of the cost of care were analyzed. 
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2.2 Inclusion criteria  
Clients who met the following inclusion criteria were identified: living in the community (not 
24-hour assisted accommodation) and treated as outpatients by community mental health 
teams; at least 3 months of continuous care in the current service; capable of giving in-
formed consent; sufficient knowledge of the language of the host country; a primary diag-
nosis of schizophrenia or related psychotic disorder (ICD-10 = F20-F29); aged between 
18 and 65 years of age (to constrain the sample to the core group of community psychia-
try and exclude patients suffering from co-morbidity such as somatic diseases or demen-
tia); meeting with their key worker at least once every two months, with the expectation 
that they would continue with the service for the next 12 months; and absence of severe 
organic psychiatric illness or primary substance abuse. Written informed consent was ob-
tained from all patients participating in the study.  
Pre-intervention data collection was from December 2002 to September 2004, and post-
intervention data was collected from December 2003 to May 2005. Patients were inter-
viewed at both time points by trained researchers (psychologists who did not belong to the 
clinical teams that were responsible for the treatment of patients), either at the relevant 
community mental health service or at home. The interviews included the whole set of 
scales and instruments as described below (see assessments). The psychologists were 
not blinded whether patients were in the experimental or control group.  
 
 
 
Organisational Characteristics of Services involved 
The population size of the involved catchment areas varied (Granada: 188,000 inhabi-
tants; Groningen: 400,000; London: 710,000; Lund: 100,000; Mannheim: 320,000; Zurich: 
382,000). Although all included countries adopted community mental health care as a 
basic concept for treating patients with schizophrenia, the actual provision of inpatient, 
outpatient or rehabilitative services differed considerably from region to region, according 
to national characteristics of mental health care delivery or other factors.  
Granada, where 3 community mental health teams (CMHT) with a total of 19 staff mem-
bers were provided to serve the patients with schizophrenia of the catchment area, was 
the least well equipped region in terms of CMHTs, psychiatric hospital beds (0.10-0.11 per 
1,000 population) or places in sheltered accommodation (0.08 per 1,000 population). 
Groningen had 4 CMHTs with 55 staff members, a psychiatric bed rate of ca. 0.4 per 
1,000 population and ca. 0.10 sheltered accommodation places per 1,000 population. The 
East London site, which collaborated in the stud offered 267 psychiatric hospital beds 
(0.37 per 1.000 population). Outpatient care in London was provided by 10 CMHTs with a 
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total of 400 staff members. In Lund, there were 4 CMHTs with 15-18 staff members each. 
The psychiatric bed rate of the Lund catchment area was 0.85 per 1,000 population and 
places in sheltered accommodation were 0.53 per 1,000 population. Outpatient mental 
health care in Mannheim and Zurich differed from the other centres, as in Germany and 
Switzerland, numerous private psychiatrists in office practice (whose treatments are cov-
ered by the Swiss or German health insurance schemes and were not disproportionally 
more expensive against those provided by outpatient departments) are strongly involved 
in outpatient mental health care. In the Zurich region alone, approx. 200 psychiatrists are 
based in office practice (ca. 0.5 per 1,000 population). Compared to other countries, this 
dense network of outpatient psychiatrists diminishes the role of German or Swiss CMHTs 
to a certain degree. On the other hand, rehabilitative and residential care is a major sector 
of mental health care both in Switzerland and Germany, where places in sheltered ac-
commodation mounted to 0.52 (Mannheim) and 1.05 (Zurich) per 1,000 population. 
Mannheim had 0.52 psychiatric hospital beds per 1,000 population, whereas the rate in 
Zurich was 0.78.  
The average case-load of a CMHT-keyworker varied also. It ranged from 8 (Zurich) 10-12 
(Mannheim, London), to 18.5 (Groningen) and 25 (Lund). Case-loads in Granada were 
probably much higher, but unfortunately case-load figures from Granada were not avail-
able. Usually, CMHTs include part- or full time psychiatric nurses or social workers. Psy-
chiatrists or psychologists are part of the teams in most, but not in all countries (e.g. for 
reasons mentioned above, not in Switzerland or Germany). Some teams add additional 
professions e.g. occupational or other therapists, while others do not provide such ser-
vices. CMHTs usually are responsible for health care planning and coordination, case 
management, supportive counselling, the prescription or application of psychotropic medi-
cation, psychotherapy, home visits or other services. Again, this differs with the national 
mental health care principles or concepts and and the capacities of regional services.  
These capacities and rates must be seen as rough estimates, as inpatient or outpatient 
capacities of catchment areas are rarely selective and tend to overlap with neighbouring 
regions. Additionally a variety of additional rehabilitative services not mentioned here may 
contribute to the various community care systems, so that the effectiveness of such core 
services as CMHTs is hard to assess from the size, composition or case-loads of the 
teams alone. Nevertheless, these figures suggest that community mental health care in 
the 6 countries provide somewhat different care on the ground. 
This cost study recorded all contacts of patients with mental health care services in the 
respective region, not only those to services described above to characterize the different 
community care concepts.  
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2.3 Study sample 
The original RCT included a total of 507 patients. Their key workers were randomly as-
signed to either the intervention or control condition in order to avoid potential contamina-
tion between intervention groups. Key workers were randomized with the use of a com-
puter generated random block number allocation sequence (to ensure an equal balance 
across sites). The randomization procedure was completed separately by each country, 
per CMHT and was stratified by professional background (Community psychiatric nurse, 
social worker, support worker etc.) and by the number of patients within each key worker's 
caseload that consented to participate.  
Overall, the intervention group included 271, the control group 236 patients. Of these pa-
tients, 451 completed the follow-up. Detailed socio-demographic and morbidity data are 
reported elsewhere (Priebe et al., 2007). Due to the randomised controlled trial design, 
there were no significant differences in the characteristics of participants in the control and 
intervention groups across all sites at baseline. Only patients with full 12-month coverage 
of utilisation data were included into the cost-analyses. Additionally to 57 drop-outs during 
the follow-up, another 29 patients had to be dropped from the final data set due to incom-
plete service use information (Granada 11, Groningen 0, London 7, Lund 3, Mannheim 6, 
Zurich 1). The final sample for cost analyses encompassed 422 patients.  
 
2.4 Assessments 
Clinical assessments as used in the original RCT to compare clinical outcomes in the con-
trol and intervention groups (Priebe et al., 2007) were seen as potential cost predictors 
and included into the cost analyses. These scales were used:  
• the Manchester Short Assessment of Quality of Life (MANSA) (Priebe et al., 1999), 
on which patients rate their satisfaction with 12 life domains on a 7-point scale 
from 1 (‘couldn’t be worse’) to 7 (‘couldn’t be better’). The mean score of all 12-
satisfaction questions was used as a cost predictor.  
• the 8-item Client Satisfaction Questionnaire (CSQ-8) (Nguyen et al., 1983) assess-
ing clients’ general satisfaction with services.  
• the Camberwell Assessment of Need Short Appraisal Schedule, patient-rated ver-
sion (CANSAS) (Slade et al.,1996) which assesses  health and social needs 
across 22 domains, the CANSAS produces two subtotal scores: ‘total unmet 
needs’ and ‘total met needs’. 
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• the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987), a 30-item, 
7- point scale from 1 (‘absent’) to 7 (‘extreme’). The PANSS comprises a global 
score, and three subscales (positive, negative, and general psychopathology). 
• Socio-demographic information and data on mastery, empowerment, self esteem, 
drug compliance, and other domains were also collected at baseline or during fol-
low-up and used as potential cost predictors. 
• Study clients’ use of mental health care services was recorded continuously for 
twelve months with the Service Utilization Sheet (SUS), which adapted the service 
items and definitions of the Client Socio-demographic and Service Receipt Inven-
tory (CSSRI) (Chisholm et al. 2000) and of the European Service Mapping Sched-
ule (ESMS) (Johnson et al., 2000). 
• Intake of psychotropic medication was assessed cross-sectionally at baseline and 
follow-up by recording the brand name and dosage of each psychotropic drug pre-
scribed for each patient. 
 
The 12-month psychotropic drug cost was estimated on the basis of the medication intake 
at baseline, assuming that possible changes in psychotropic drug prescription were lev-
elled out across the sample and intake patterns at the group level remained more or less 
stable over time. Prior to assigning cost estimates, depot medication was converted into 
average doses of mg per day. To avoid double costing, intake and costs of psychotropic 
drugs were adjusted for inpatient stays, during which medication is covered by hospital 
fees or rates.  
Patient-level cost profiles were calculated by weighting all service contacts during the fol-
low-up with country- or centre-specific unit-cost estimates, which were derived from na-
tional data sources. To assign cost estimates for psychotropic drugs, the lowest national 
market price for the respective drug was used. All cost data was transformed into € as a 
single currency using conversion rates from January 1, 2004. To eliminate price-level dif-
ferences between countries, PPP-conversion rates (power purchase parities) were used, 
which are routinely calculated by the OECD and provided by the Statistical Office of the 
European Communities. 
 
2.5 Statistical cost analyses 
The total cost of care was adjusted for socio-demographic and clinical variables to control 
for inter-site differences of samples. Due to non-normal errors of the cost variables to be 
analysed, standard linear regression for analysing the association of costs and socio-
demographic or clinical characteristics were avoided. Instead, cost data were first log-
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transformed and then analysed by means of linear regression (log-normal model). For a 
better clearness of the model-parameters, a generalised linear model (GLM) was fitted 
additionally (Austin et al., 2003), using a gamma distribution and a logarithmic link func-
tion. Other than log-normal models, gamma models allow to process cost-data in its origi-
nal scale. To analyse data with both of the models can be viewed as an ad hoc robust-
ness analysis (Wiens, 1999). Coefficients derived from these models may be compared 
directly and are to be interpreted as the logarithm of the relative change in cost associated 
with a one-unit change in the predictor variable (or: exponential coefficients provide esti-
mated percentage increases in costs). Goodness-of-fit was assessed by the deviance 
indicating a good fit in case of low values.  
Variables for inclusion into the GLM were selected according to their potential influence 
on costs of care during the follow-up. For detailed results of the variables used as cost 
predictors see table 1 or Priebe et al. (2007). The (regression) model selection was done 
in a stepwise procedure. Thus, p-values of the predictors in the final models should be 
interpreted in an exploratory manner. 
 
 
3. Results 
 
Major socio-demographic and disorder related characteristics of the patients are shown in 
table 1. Utilisation of mental health care services - which provided the basic data for all 
cost calculations - varied considerably across sites (Table 2). After transforming service 
utilisation data into cost-of-care data and adjusting for power purchase parities (PPP), 
there were sizeable inter-site differences in the total cost of mental health care and in 
most of the service types analysed. Average annual costs of mental health care were low-
est in Granada (Spain) and highest in Zurich (Switzerland), where total costs were more 
than tenfold higher(Fig.1).  
 
 
Table 1 about here  
 
 
Table 2 about here  
 
 
Figure 1 about here  
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Numerically, the average costs of psychotropic medication was much more constant 
across sites, whereas the average costs of other services, e.g., hospital or outpatient 
care, or sheltered accommodation, differed remarkably (see Fig.1). Drug costs claimed a 
greater proportion of the mental health care costs, the smaller the total cost of care of the 
respective site was. In Granada, nearly 40% of all costs were accounted for by antipsy-
chotics or other psychotropic drugs, whereas in Zurich this proportion was only 4.6 % (see 
Fig. 2).  
The cost proportions for first- and second-generation antipsychotics were clearly in favour 
of the latter and more or less constant across sites, with the exception of the Spanish cen-
tre, where the proportion spent on second-generation antipsychotics was far lower (see 
Table 3). The proportion of patients prescribed with second-generation antipsychotics was 
61,1 % across all sites. 44,1 % of all patients were treated with first generation antipsy-
chotics and 14 % took both drugs. These proportions differed between centres. Zurich 
showed had the largest proportion of patients taking second-generation antipsychotics 
(84.3%) and the smallest first-generation group 27.1 %. In Granada it was the opposite 
(42.8 % of all patients taking second-generation- and 62.5 % first-generation antipsychot-
ics). The highest share of patients taking both types of agents was identified in Lund 
(23.6%). 
 
 
Figure 2 about here 
 
Table 3 about here  
 
 
To explore this cost variation further, regression models were fitted separately for two de-
pendent variables:  
• total cost of care, and  
• medication costs of psychotropic drug intake.  
Tables 4 and 5 show the gamma and log normal regression models for total cost of care 
and medication cost respectively that were calculated due to the skewed distribution of the 
cost data (see methods section). The tables show only predictors from the total set of 
variables that proved to be significant at p≤0.05 during the model selection procedure in at 
least one model (boldface). All centre-variables were tested against the Zurich centre, 
which was used as a statistical benchmark due to its high costs. 
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Table 4 about here  
 
 
 
The exponential coefficients Exp(β) of the gamma or the log-normal models express the 
percentage of cost increase or decrease. Thus, the more than tenfold lower mental health 
care costs in Granada compared to Zurich proved to be significant. Similarly, both models 
confirm the cost in Groningen as being roughly one third of the cost in Zurich, in London 
as one quarter, in Lund as two thirds and in Mannheim as approximately half of the costs 
in Zurich (see Tab.4). Additionally, according to these models, each additional year of age 
reduces the total mental health care cost of a patient by roughly one percent. But being in 
sheltered accommodation increases the costs by 71%, whereas a self-earned income or 
salary cuts the total cost of care by half.  
The influence of disorder-related estimates was much lower: each additional negative 
symptom (PANSS) increases the total care costs by a mere 1.5 %, whereas treatment 
compliance had a higher influence on costs. However, only the gamma model confirmed 
this as a significant predictor, while the log-normal model did not.  
The intervention from the original RCT (Priebe et al., 2007) proved to have no significant 
influence on the total care cost: the allocation variable (indicating the experimental or the 
control group) showed only a trend towards significance in the gamma model (p≤0.10) 
and was above the 0.10 level in the log-normal model. Due to the constituent character of 
this variable for the original RCT, it was retained in the model and shown here, although 
from a health-economics perspective it is not statistically significant.  
 
 
Table 5 about here  
 
 
 
The two regression models predicting the medication cost (Tab. 5) showed that the influ-
ence of the site-variable is considerably less, since the costs of psychopharmacologic 
drug intake in Lund and Mannheim did not differ significantly from those in Zurich in both 
statistical models. Only Granada and Groningen showed a drug cost pattern significantly 
less costly than that of Zurich (shown by both models), whereas the difference with Lon-
don was confirmed only by the log-normal model.  
The association between medication costs and drug compliance at baseline was signifi-
cant. A change from poor to average, or from average to good compliance was associated 
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with an overall decrease of drug costs by 29% (confirmed by the gamma model, but not 
by the log-normal model). Finally, drug costs were associated with needs for care: each 
additional domain in which the patient thought professional help was needed increased 
costs by 11% to 22%.  
 
 
4. Discussion  
The study confirms the remarkable differences in the total costs of mental health care for 
patients with schizophrenia across European countries. This is the case even though the 
participating patients were homogeneous with respect to diagnosis and other characteris-
tics and all of the relevant countries agree on community mental health care as a basic 
concept for treating patients with schizophrenia. We found considerably higher inter-site 
differences than in earlier pan-European projects (Knapp et al. 2002). However, regional 
cost of care did not exceed the ranges found in earlier national studies (Haro et al., 1998; 
Salize & Rössler, 1996; Salvador-Carulla et al., 1998; Stant et al., 2003; Vazquez-Polo et 
al., 2005). Compared to earlier multi-center studies, this study has some methodological 
advantages which include a long follow-up and recording period of service utilisation (a 
full 12 months) and the inclusion of detailed medication costs. Different price levels across 
countries were balanced out by power purchase parities. A weak influence of different 
salary scales for health workers or other factors could not completely be ruled out, but 
they are unlikely to account for the huge variation in total costs.  
 
Service provision and consequently service use differed remarkably between the included 
regions. Although all of the countries practice community care, many reasons may ac-
count for the differences across the psychiatric systems: different starting points or spe-
cific aims of the national psychiatric reforms, different organisational characteristics of 
overall health care delivery, different financing structures, different mental health care 
budgets or economic constraints etc.   
Although patients with schizophrenia have a wide range of needs which may vary indi-
vidually by amount and type, our results suggest that the in principle elastic demand curve 
of psychiatric care show a clear tendency to follow the regional availability of services. 
Thus, the cost of care patterns reflect more or less different national mental health care 
concepts and the characteristic range of services to be found in the participating regions 
and countries, rather than patient psychopathology or the actual needs for care. Particu-
larly, unmet needs did not have a significant influence on total care costs. If this had been 
the case, it might have suggested deficient mental health care in regions with low costs, 
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e.g. in Granada. However, unmet needs were highest in London, and not in the Spanish 
centre where costs were lowest.  
Of course, where services are not available, expenses for them cannot be incurred. How-
ever, an absence of specific services does not necessarily mean that treatments such 
services usually offer are not needed. But when specific services for these needs are not 
available they tend to be overlooked as a need that requires measures by the professional 
care system. For example, among other factors, the considerable differences in the avail-
ability and use of sheltered accommodation services may be explained by cultural as-
pects. Families, particularly in southern European countries such as Spain, are tradition-
ally involved – usually at their own expenses - in caring for the chronically mentally ill to a 
much higher degree than in other European countries. In Middle Europe or Scandinavia, a 
more pronounced societal trend towards weaker family ties may support the implementa-
tion of professional residential services as an essential part of community mental health 
care.  
As a consequence, total costs of care cannot be seen as an indicator for the quality or 
effectiveness of psychiatric care in a particular region and even less so in cross-border 
comparisons – at least not on the level of analyses that was done here. For identifying an 
association between costs and quality of care much better indicators of the global effec-
tiveness of mental health care systems are required than are currently available. Such 
indicators must cover informal care or any relevant contribution of families and relatives.  
 
Although the effectiveness of the mental health care systems or the commensurability of 
total care costs cannot finally be decided on this level, the second set of regression analy-
ses (on psychopharmacologic costs) in this study does indicate an association between 
quality of care and costs. In these regression models centre effects show far less influ-
ence on medication costs than they did on the total care costs, despite the considerable 
proportion that medication costs claim of the total mental health care budgets. In the case 
of Granada where rehabilitative services or sheltered accommodation are scarce, expen-
ditures for medication rose to nearly 40% of the total expenditure. Medication costs as 
high as that may reduce the options for prescribing costly second-generation antipsychot-
ics, which accounted for the majority of psychopharmacologic drug costs at all other sites. 
These issues are worthy of further exploration. 
This relative stability of medication costs compared to the total cost of care may have 
several reasons. First of all, psychopharmacologic drugs represent the backbone of 
schizophrenia treatment that requires the lowest infrastructure of all psychiatric care mo-
dalities. So it would probably be the last of all treatments to be curtailed when cost con-
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straints limit mental health care spending. Furthermore, a relatively solid evidence base 
for the effectiveness of antipsychotic drug treatment is recognised worldwide supporting 
the homogenisation of drug treatment and the associated costs internationally. Another 
explanation may be that drug prescription is one of the few sectors of mental health care 
in which prices are predominantly market driven and far less state regulated than in most 
other sectors or services where costs may vary according to national health policies, 
health insurance schemes or public health care spending. Additionally, homogenized 
price policies of the internationally operating pharmacological companies may contribute 
to the stability of medication costs. 
All in all, the huge overall cost differences as found in this study should be reason enough 
to stimulate research on the factors that influence service provision, costs and their link-
age with outcomes in greater depth and detail (Washburn 2008, Möller 2008, Carpenter & 
Buchanan 2008).  For this purpose, it is essential to build an evidence base for the effec-
tiveness of the service types or treatments for schizophrenic patients in the various care 
models, and to develop good indicators for their effectiveness on a system level.  
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Clinic Trial registration information: trial number ISRCTN75571732 
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Table 1 Baseline socio-demographic characteristics of patients, means (standard devia-
tion SD) or proportions (%)   
(Mansa: Manchester Short Assessment of Quality of Life, CSQ: Client Satisfac-
tion Questionnaire, Cansas: Camberwell Assessment of Need Short Appraisal 
Schedule, PANSS: Positive and Negative Syndrome Scale) 
 
 
 Mean (SD) or Proportion  
Patients (n) 422 
  
Mean Age (years)  42.3 (11.3) 
Gender (% female) 31.8 %  
Marital status (% single) 70.8 % 
Unemployed (%) 36.7 % 
Employed (incl. Sheltered Work) 29.4 % 
Diagnosis  
Undifferentiated Schizophrenia 35.1 % 
Paranoid Schizophrenia 30.1 % 
Other Schizophrenia (Schizoaffective, Delusional etc.) 18.4 % 
Other Non-Organic Psychotic Disorder 16.4 % 
  
Length of illness (years) 16,0 (10.1) 
Number of hospital admissions 5.2 (7.1) 
Quality of Life (MANSA) 4.7 (0.8) 
Satisfaction with treatment (CSQ) 25.7 (4.2) 
Unmet needs (CANSAS) 2.7 (2.8) 
  
PANSS Subscales  
Positive  14.8 (5.7) 
Negative 16.6 (6.7) 
General 32.4 (9.6) 
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Table 2 Mental health care service utilization across sites (average frequency of con-
tacts with  or days spent in service per patient during the 12-month follow-up)  
(CMHC: Community Mental Health Centre) 
 
 
 
 Granada Groningen London Lund Mannheim Zurich 
Sample size 56 94 81 55 66 70 
       
Psychiatric Hospital 0.9 18.1 7.8 2.8 13.4 6.2 
Emergency/Crisis Ward 0.1 0 0 0.1 0.1 0.2 
General Medical Wards 0 0 0 0 0 0 
Other Inpatient Services 0 0 0 0.9 0 0 
Total hospital days 0.88 18.17 7.78 3.78 13.38 6.27 
       
Outpatient Visits 0 0.2 0 42.3 0.4 19.3 
Day/Night Hospital 1.4 0 0 12.1 2.1 1.9 
Other outpatient services 0 0.1 0 3.9 0.2 0.6 
       
CMHC 7.4 32.4 24.2 15 5 0.6 
Day Care 25.9 30 6.1 12.4 56.5 1.6 
Sheltered Workshop 4.6 3.6 1.7 8.7 53.8 107.1 
Sheltered Education Service 0.1 0.5 0.7 5.9 4.6 1.2 
Other day services 0 0 0 0.1 21.3 14.1 
       
Psychiatrists 0 0 0 0.7 13 3.3 
Psychologists 0 0 0 2.1 2.4 1.1 
Primary Care Physicians 3.7 0.3 0 0.4 1.8 0.9 
Psychiatric Nurses 0 0 0 1.2 1.9 0.1 
Social Worker 0 0 0 0.2 0.8 0.3 
Occupational Therapists 0 0 0 1.4 2.1 1.9 
District Nurses 0 0 0 0.3 2.9 6.9 
Home Help 0 0.6 1.1 7.2 1 2.4 
Other Services 0 0 0 0.3 2 8.2 
       
Overnight 24h staffed 0 0 0.7 13.3 2.8 26.6 
Overnight not 24h staffed 0 2.9 0 13.0 276.1 135.4 
Overnight not staffed 0 0 0 0 0 12.9 
Other home 0 0 0 0 0 15.4 
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Tab. 3 Cost proportions for first- and second-generation antipsychotics across sites 
(100% = average annual medication cost per patient) 
 
 Granada Groningen London Lund Mannheim Zurich 
% second generation antipsychotics 49.4 % 80.0 % 80.5 % 64.8 % 81.3 % 74.5 % 
% first generation antipsychotics 38.9 % 9.7 % 8.7 % 8.6 % 10.9 % 5.5 % 
 % other psychotropic drugs 11.8 % 10.3 % 10.8 % 26.6 % 7.8 % 20.0 % 
Total medication cost (100%) 1 181.27 767.98 1 483.70 1 947.08 2 019.46 1 695.40
 
 
 
 
Tab. 4 Regression model for predictors of total costs of mental health care (coefficients 
in boldface are significant at p≤0.05)   
(PANSS: Positive and Negative Syndrome Scale) 
 
 
variable gamma model log-normal model 
 β Exp(β) β Exp(β) 
Centre 1 (Granada) 1 - 2.3228 0.0980 - 2.3974 0.0912 
Centre 2 (Groningen) 1 - 0.9674 0.3801 - 1.1207 0.3261 
Centre 3 (London) 1 - 1.4285 0.2397 - 1.5398 0.2144 
Centre 4 (Lund) 1 - 0.3952 0.6735 - 0.4260 0.6531 
Centre 5 (Mannheim) 1 - 0.6985 0.4973 - 0.5728 0.5639 
Age - 0.0112 0.9888 - 0.0099 0.9902 
Living situation 0.5376 1.7119 0.5488 1.7312 
Main income source - 0.8411 0.4312 - 0.7366 0.4788 
Panss negative score follow-up 0.0141 1.0142 0.0160 1.0161 
Treatment adherence baseline  0.1955 1.2159 0.0568 1.0584 
allocation to experimental group 0.1545 1.1671 0.1373 1.1472 
     
Deviance  282.62  290.09  
1 Compared against Centre 6 (Zurich, Switzerland) 
 
 
Table 5 Regression model for predictors of average medication costs (coefficients in bold 
are significant at p≤0.05) 
 
Variable gamma model log-normal model 
 β Exp(β) β Exp(β) 
Centre 1 (Granada) 1 - 0.3962 0.6792 - 0.6287 0.5333 
Centre 2 (Groningen) 1 - 0.7299 0.4820 - 1.4049 0.2454 
Centre 3 (London) 1 - 0.1168 0.8900 - 0.4969 0.6084 
Centre 4 (Lund) 1 0.0792 1.0824 - 0.2216 1.8012 
Centre 5 (Mannheim) 1 0.2133 1.2378 0.0698 1.0723 
Age - 0.0121 0.9880 - 0.0126 0.9875 
No. of domains help needed  - 0.1053 1.1110 - 0.1990 1.2202 
Drug compliance baseline  - 0.0798 0.9233 - 0.3360 0.7146 
     
Deviance  526.34  937.05  
1 Compared against Centre 6 (Zurich, Switzerland) 
